SYNDAX PHARMACEUTICALS INC
NASDAQ: SNDX (Syndax Pharmaceuticals, Inc.)
Last update: 1 hour ago18.18
-0.64 (-3.40%)
| Previous Close | 18.82 |
| Volume | 1,223,076 |
| Price / Sales | 6.55 |
| Price / Book | 111.30 |
| 52 Weeks Range |
| Operating Margin (TTM) | -416.67% |
| Diluted EPS (TTM) | -3.85 |
| Total Debt/Equity (MRQ) | 160.71% |
| Current Ratio (MRQ) | 5.80 |
| Operating Cash Flow (TTM) | -286.52 M |
| Levered Free Cash Flow (TTM) | -169.65 M |
| Return on Assets (TTM) | -36.29% |
| Return on Equity (TTM) | -93.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Syndax Pharmaceuticals, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.50 |
|
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.29% |
| % Held by Institutions | 120.71% |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |